Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

Original publication

DOI

10.1016/j.ahj.2014.03.021

Type

Journal article

Journal

Am Heart J

Publication Date

07/2014

Volume

168

Pages

23 - 9.e2

Keywords

Acarbose, Blood Glucose, Coronary Disease, Diabetes Mellitus, Type 2, Disease Progression, Double-Blind Method, Follow-Up Studies, Glucose Intolerance, Humans, Hypoglycemic Agents, Prospective Studies, Secondary Prevention, Treatment Outcome